UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of March 2026
Commission file number: 001-42389
BIOHARVEST SCIENCES INC.
(Exact name of Registrant as specified in its charter)
Not applicable
(Translation of Registrant’s name into English)
1140-625 Howe Street, Vancouver, British Columbia V6C 2T6, Canada
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
☐ Form 20-F ☒ Form 40-F
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
SUBMITTED HEREWITH
Exhibits:
Exhibit
| Description
|
99.1
| Material Change Report dated March 6, 2026
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BIOHARVEST SCIENCES INC.
|
| (Registrant)
|
|
|
Date: March 6, 2026
| /s/ David Ryan
|
| Name: David Ryan
|
| Title: Vice-President, Investor Relations & Secretary
|
FORM 51-102F3
MATERIAL CHANGE REPORT
Item 1.Name and Address of Company
BIOHARVEST SCIENCES INC.
Suite 1140 – 625 Howe Street
Vancouver, BC, V6C 2T6
(the “Company” or “BioHarvest”)
Item 2.Date of Material Change
March 3, 2025.
Item 3.News Release
The news release was issued on March 5, 2026 and disseminated by Newsfile Corp.
Item 4.Summary of Material Change
The Company announced changes to it’s board of directors.
Item 5.Full Description of Material Change
The Company announced the resignation of David Tsur as a director of the Company. Mr. Tsur served as a director since 2021. The Company also announced the immediate appointment of Prof. Hezi Levy to replace Mr. Tsur on its board of directors.
Prof. Levy joins the Board with decades of leadership experience across Israel’s healthcare system. A physician by education, Prof. Levy previously served as Director General of the Israeli Ministry of Health, including during the COVID-19 pandemic, where he played a central role in guiding national healthcare policy. Prof. Levy also served as Head of the Medical Corps of the Israel Defense Forces (IDF) with the rank of Brigadier General and was the General Manager of Barzilai Medical Center for many years, overseeing one of Israel’s major hospitals and complex healthcare operations.
Item 6.Reliance on Subsection 7.1(2) of National Instrument 51-102
Not applicable.
Item 7.Omitted Information
None.
Item 8.Executive Officer
For further information, please contact:
David Ryan
Secretary and VP, Investor Relations
604 622-1187
Item 9.Date of Report
March 6, 2026.